BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

PHARNEXT Raises Eur 4.8 Million Series A Funding


6/9/2010 6:57:32 AM

PARIS--(BUSINESS WIRE)--Pharnext SAS, a biopharmaceutical company specializing in the development of innovative treatments based on Pleotherapy™ for severe neurological diseases, today announced that it had closed a €4.8-million Series A round of funding on June 3rd (corresponding to a company valuation of €45 million). Part of the fresh investment was provided by Pharnext's co-founding investor Truffle Capital, which remains the majority shareholder. The remaining were contributed by Aurinvest Capital 2, Financière Boscary and a group of some of France's best-known entrepreneurs - Charles Beigbeder (founder of Selftrade, Poweo, Audacia and AgroGeneration), Claude Darmon (former President of the CEGELEC group) and Olivier Fulconis (former Executive VP and Chief Marketing Officer at Converteam).

This round of fundraising will enable Pharnext to consider launching the first-in-man clinical trials of its Pleodrug™ in the treatment of Charcot-Marie-Tooth disease before the end of 2010. Charcot-Marie-Tooth disease is a chronic, severe, invalidating neuromuscular disease which affects 3 million people worldwide and for which there is no cure at present. The fundraising will also help initiate and/or continue in vitro and in vivo research programmes on the use of Pleodrugs™ in other serious pathologies: Alzheimer's disease, chemotherapy-induced peripheral neuropathy, polycystic kidney disease, amyotrophic lateral sclerosis, hyperlipidaemia and diabetes.

Pharnext has particularly solid financial foundations:

- a €2.5-million round of seed fundraising with Truffle Capital (December 2007).

- two agreements with the pharmaceutical group Ipsen, potentially worth up to €94 million in upfront and milestone payments (June 2009).

- an initial grant for work on Charcot-Marie-Tooth disease from Oséo, the French state innovation agency (2007).

- a grant from the French Muscular Dystrophy Association (AFM, 2009).

Pharnext has designed a novel, proprietary platform (Pleotherapy™) based on network pharmacology. The company's discovery engine identifies rational drug combinations (Pleodrugs™) made up of individual Pleocompounds™. This innovative approach could provide a solution to the ongoing and worrying decline in pharmaceutical pipeline productivity.

About Pharnext

Pharnext is a biopharmaceutical company focused on discovering, developing and licensing new pharmaceutical treatments based on intelligent Pleocompounds™ that form the basis of Pleodrugs™.

Contact:

PHARNEXT Professor Daniel Cohen, +33 1 55 42 62 00 / 03 daniel.cohen@pharnext.com or ALIZE RP Caroline Carmagnol, +33 6 64 18 99 59 caroline@alizerp.com

Read at BioSpace.com

PHARNEXT
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->